2024
Synergistic effects of sulopenem in combination with cefuroxime or durlobactam against Mycobacterium abscessus
Dousa K, Shin E, Kurz S, Plummer M, Nantongo M, Bethel C, Taracila M, Nguyen D, Kreiswith B, Daley C, Remy K, Holland S, Bonomo R. Synergistic effects of sulopenem in combination with cefuroxime or durlobactam against Mycobacterium abscessus. MBio 2024, 15: e00609-24. PMID: 38742824, PMCID: PMC11237399, DOI: 10.1128/mbio.00609-24.Peer-Reviewed Original ResearchConceptsD,D-carboxypeptidaseMinimum inhibitory concentrationB-lactamPenicillin-binding-proteinCell wall synthesisL,D-transpeptidasesResistance to common antibioticsLowest minimum inhibitory concentrationWall synthesisCystic fibrosisD-carboxypeptidaseMass spectrometry analysisB-lactamaseThioester bondRate of treatment failureCell-based assaysMultiple antibioticsB-lactam ringsCommon antibioticsD-transpeptidasesB-lactamase inhibitorsCysteine residuesTime-kill studiesStructural lung diseaseMultidrug-resistant tuberculosis
2022
Inhibiting Mycobacterium abscessus Cell Wall Synthesis: Using a Novel Diazabicyclooctane β-Lactamase Inhibitor To Augment β-Lactam Action
Dousa K, Nguyen D, Kurz S, Taracila M, Bethel C, Schinabeck W, Kreiswirth B, Brown S, Boom W, Hotchkiss R, Remy K, Jacono F, Daley C, Holland S, Miller A, Bonomo R. Inhibiting Mycobacterium abscessus Cell Wall Synthesis: Using a Novel Diazabicyclooctane β-Lactamase Inhibitor To Augment β-Lactam Action. MBio 2022, 13: e03529-21. PMID: 35073757, PMCID: PMC8787486, DOI: 10.1128/mbio.03529-21.Peer-Reviewed Original ResearchConceptsD-carboxypeptidaseB-lactamB-lactamaseDisrupt cell wall synthesisStable acyl-enzyme complexesCell wall synthesisAcyl-enzyme complexMichaelis-Menten complexB-lactamase inhibitorsWall synthesisPeptidoglycan synthesisStructural lung diseaseTriple drug combinationIsolates to amoxicillinCell-based assaysMycobacterium abscessusMIC rangeImipenemMichaelis constantAcylation rateInhibitor combinationsDurlobactamMultidrug resistanceTherapeutic regimensCystic fibrosis
2021
“One-Two Punch”: Synergistic ß-Lactam Combinations for Mycobacterium abscessus and Target Redundancy in the Inhibition of Peptidoglycan Synthesis Enzymes
Nguyen D, Dousa K, Kurz S, Brown S, Drusano G, Holland S, Kreiswirth B, Boom W, Daley C, Bonomo R. “One-Two Punch”: Synergistic ß-Lactam Combinations for Mycobacterium abscessus and Target Redundancy in the Inhibition of Peptidoglycan Synthesis Enzymes. Clinical Infectious Diseases 2021, 73: 1532-1536. PMID: 34113990, PMCID: PMC8677594, DOI: 10.1093/cid/ciab535.Peer-Reviewed Original ResearchConceptsPeptidoglycan synthesis enzymesMinimum inhibitory concentration of clinical isolatesB-lactamCombination of imipenemSynthesis enzymesSynergistic in vitroClinical isolatesMinimum inhibitory concentrationMycobacterium abscessusClinical trialsMycobacterial infectionAbscessusEnzymeCeftarolineImipenem
2020
Drug-Resistant Tuberculosis A Glance at Progress and Global Challenges
Dousa K, Kurz S, Bark C, Bonomo R, Furin J. Drug-Resistant Tuberculosis A Glance at Progress and Global Challenges. Infectious Disease Clinics Of North America 2020, 34: 863-886. PMID: 33011048, DOI: 10.1016/j.idc.2020.06.001.Peer-Reviewed Original ResearchConceptsSecond-line medicationsMultidrug-resistant Mycobacterium tuberculosisDrug susceptibility predictionOral formulationMultinational trialDrug resistancePublic health threatEconomic burdenDiagnostic techniquesTuberculosisAdequate clinical resourcesClinical resourcesHealth threatLaboratory servicesSummary for Clinicians: 2020 Clinical Practice Guideline Summary for the Treatment of Nontuberculous Mycobacterial Pulmonary Disease.
Kurz S, Zha B, Herman D, Holt M, Daley C, Ruminjo J, Thomson C. Summary for Clinicians: 2020 Clinical Practice Guideline Summary for the Treatment of Nontuberculous Mycobacterial Pulmonary Disease. Annals Of The American Thoracic Society 2020, 17: 1033-1039. PMID: 32870060, DOI: 10.1513/annalsats.202003-222cme.Peer-Reviewed Original ResearchTime to Expand the Picture of Mycobacterial Lipids: Spotlight on Nontuberculous Mycobacteria
Kurz S, Rivas-Santiago B. Time to Expand the Picture of Mycobacterial Lipids: Spotlight on Nontuberculous Mycobacteria. American Journal Of Respiratory Cell And Molecular Biology 2020, 62: 275-276. PMID: 31580721, PMCID: PMC7055696, DOI: 10.1165/rcmb.2019-0324ed.Peer-Reviewed Original Research
2019
The effect of respiratory viral assay panel on antibiotic prescription patterns at discharge in adults admitted with mild to moderate acute exacerbation of COPD: a retrospective before- after study
Tickoo M, Ruthazer R, Bardia A, Doron S, Andujar-Vazquez GM, Gardiner BJ, Snydman DR, Kurz SG. The effect of respiratory viral assay panel on antibiotic prescription patterns at discharge in adults admitted with mild to moderate acute exacerbation of COPD: a retrospective before- after study. BMC Pulmonary Medicine 2019, 19: 118. PMID: 31262278, PMCID: PMC6604457, DOI: 10.1186/s12890-019-0872-0.Peer-Reviewed Original ResearchConceptsRespiratory viral panelChronic obstructive pulmonary diseaseObstructive pulmonary diseaseAntibiotic prescriptionsAcute exacerbationPulmonary diseaseViral panelAntibiotic prescription patternsPositive smoking statusAntibiotic prescription ratesProportion of patientsObstructive sleep apneaTertiary medical centerStudy of patientsUse of antibioticsAECOPD patientsConclusionsIn patientsPrescription patternsPrescription ratesPrimary outcomeSingle centerSleep apneaSmoking statusMean ageResultsA total
2016
Drug-Resistant Tuberculosis Challenges and Progress
Kurz S, Furin J, Bark C. Drug-Resistant Tuberculosis Challenges and Progress. Infectious Disease Clinics Of North America 2016, 30: 509-522. PMID: 27208770, PMCID: PMC4876017, DOI: 10.1016/j.idc.2016.02.010.Peer-Reviewed Original ResearchConceptsEmergence of drug-resistant tuberculosisCombination drug regimensEmergence of drug-resistant strainsDrug-resistant tuberculosisDrug-resistant strainsSpontaneous chromosomal mutationsCase of Mycobacterium tuberculosisDrug regimensClinical developmentAntimicrobial resistanceSupervised therapyChromosomal mutationsTB controlResistance mechanismsRegimensTherapy
2013
Can Inhibitor-Resistant Substitutions in the Mycobacterium tuberculosis β-Lactamase BlaC Lead to Clavulanate Resistance?: a Biochemical Rationale for the Use of β-Lactam–β-Lactamase Inhibitor Combinations
Kurz S, Wolff K, Hazra S, Bethel C, Hujer A, Smith K, Xu Y, Tremblay L, Blanchard J, Nguyen L, Bonomo R. Can Inhibitor-Resistant Substitutions in the Mycobacterium tuberculosis β-Lactamase BlaC Lead to Clavulanate Resistance?: a Biochemical Rationale for the Use of β-Lactam–β-Lactamase Inhibitor Combinations. Antimicrobial Agents And Chemotherapy 2013, 57: 6085-6096. PMID: 24060876, PMCID: PMC3837893, DOI: 10.1128/aac.01253-13.Peer-Reviewed Original ResearchMeSH KeywordsAmino Acid SubstitutionAntitubercular Agentsbeta-Lactamase Inhibitorsbeta-LactamasesClavulanic AcidDrug Therapy, CombinationEscherichia coliExtensively Drug-Resistant TuberculosisGene ExpressionHumansMeropenemMicrobial Sensitivity TestsMutagenesis, Site-DirectedMycobacterium tuberculosisProtein EngineeringRecombinant ProteinsThienamycinsConceptsInhibitor combinationsResistance to clavulanic acidMultidrug resistanceDrug resistanceClavulanic acidExtensively drug-resistant M. tuberculosis strainsEmergence of multidrug resistanceCombination of meropenemDrug-resistant M. tuberculosis strainsPresence of ampicillinAmino acid residuesExtensively drug-resistantM. tuberculosis strainsNovel treatment strategiesInhibition of growthPotential therapeutic targetTreatment regimensTherapeutic modalitiesTreatment strategiesInhibitor resistanceM. tuberculosisEnzymatic assayImpaired inhibitionTherapeutic targetAcid resistance
2012
Reappraising the use of β-lactams to treat tuberculosis
Kurz S, Bonomo R. Reappraising the use of β-lactams to treat tuberculosis. Expert Review Of Anti-infective Therapy 2012, 10: 999-1006. PMID: 23106275, PMCID: PMC3728824, DOI: 10.1586/eri.12.96.Peer-Reviewed Original Research
2011
Are We Ready for Novel Detection Methods to Treat Respiratory Pathogens in Hospital-Acquired Pneumonia?
Endimiani A, Hujer K, Hujer A, Kurz S, Jacobs M, Perlin D, Bonomo R. Are We Ready for Novel Detection Methods to Treat Respiratory Pathogens in Hospital-Acquired Pneumonia? Clinical Infectious Diseases 2011, 52: s373-s383. PMID: 21460299, PMCID: PMC3106236, DOI: 10.1093/cid/cir054.Peer-Reviewed Original ResearchConceptsHospital-acquired pneumoniaGenetic determinants of antimicrobial resistanceDeterminants of antimicrobial resistanceAntimicrobial susceptibility testingAntibiotic-resistant pathogensHospital-acquired bacterial pneumoniaPathogen-directed therapyDifficult treatment challengeCharacterize pathogensResults of cultureSusceptibility testingDiagnosis of pneumoniaEmpirical therapyAntimicrobial resistancePathogensHospital-acquiredPulmonary microbiomeBacterial pneumoniaMolecular diagnosticsPolymerase chain reactionTreatment challengesMolecular testingRespiratory pathogensPneumoniaChain reaction
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply